Kariya Pharmaceuticals ApS Financials, key figures and credit report
Gross profit -32 093.2 kDKK FY 2025 -785.4% vs 2024
EBIT -32 675.9 kDKK FY 2025 -652.7% vs 2024
Net debt 702.2 kDKK FY 2025 +160.7% vs 2024
Quick ratio 0.6 FY 2025 -1.7 vs 2024
Income statement (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | -2 712.24 | -13 798.22 | -10 223.06 | -3 624.68 | -32 093.19 |
| Employee benefit expenses | - 505.58 | -13.66 | -66.55 | - 716.29 | - 582.75 |
| Total depreciation | -7.81 | -7.81 | |||
| EBIT | -3 225.63 | -13 819.70 | -10 289.62 | -4 340.97 | -32 675.93 |
| Other financial income | 4.89 | 6.60 | 197.72 | 9.01 | 10.44 |
| Other financial expenses | - 648.60 | - 811.51 | -1 801.35 | - 215.56 | -85.88 |
| Pre-tax profit | -3 869.34 | -14 624.60 | -11 893.25 | -4 547.51 | -32 751.37 |
| Income taxes | 614.26 | 619.03 | 3 870.70 | 1 948.10 | 6 261.12 |
| Net earnings | -3 255.08 | -14 005.57 | -8 022.55 | -2 599.41 | -26 490.25 |
Assets (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Intangible assets total | |||||
| Machinery and equipment | 7.81 | ||||
| Tangible assets total | 7.81 | ||||
| Investments total | |||||
| Long term receivables total | |||||
| Inventories total | |||||
| Current trade debtors | 43.75 | 43.75 | |||
| Current owed by particip. interest comp. | 48.00 | 50.54 | |||
| Prepayments and accrued income | 6.71 | 43.43 | 45.80 | 33 373.27 | |
| Current other receivables | 75.91 | 1 412.68 | 432.65 | 150.55 | 16.62 |
| Current deferred tax assets | 5 500.00 | ||||
| Short term receivables total | 130.62 | 1 412.68 | 519.83 | 240.10 | 38 940.43 |
| Cash and bank deposits | 913.33 | 792.18 | 1 481.61 | 2 063.55 | 4.13 |
| Cash and cash equivalents | 913.33 | 792.18 | 1 481.61 | 2 063.55 | 4.13 |
| Balance sheet total (assets) | 1 051.76 | 2 204.86 | 2 001.44 | 2 303.65 | 38 944.56 |
Equity and liabilities (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Share capital | 40.00 | 40.00 | 45.82 | 48.29 | 48.29 |
| Retained earnings | -9 511.42 | -12 766.50 | 1 588.25 | 3 834.80 | 1 235.39 |
| Profit of the financial year | -3 255.08 | -14 005.57 | -8 022.55 | -2 599.41 | -26 490.25 |
| Shareholders equity total | -12 726.50 | -26 732.07 | -6 388.47 | 1 283.67 | -25 206.58 |
| Non-current loans from credit institutions | 11 320.71 | 11 886.75 | |||
| Non-current liabilities total | 11 320.71 | 11 886.75 | |||
| Current trade creditors | 201.67 | 15 280.06 | 7 424.83 | 83.33 | 63 202.77 |
| Current owed to participating | 2 217.68 | 1 745.12 | 951.81 | 907.42 | 706.34 |
| Other non-interest bearing current liabilities | 38.19 | 25.00 | 13.27 | 29.22 | 242.02 |
| Current liabilities total | 2 457.54 | 17 050.18 | 8 389.91 | 1 019.98 | 64 151.13 |
| Balance sheet total (liabilities) | 1 051.76 | 2 204.86 | 2 001.44 | 2 303.65 | 38 944.56 |
Secure checkout
Buy AI Credit Risk Report
Pay by card and the report is generated automatically and sent to your email. One-time payment – no subscription.
How it works
- 01 You pay €3 (incl. VAT) securely by card via Stripe.
- 02 You enter your email address in Stripe's payment window – the report is sent there.
- 03 The report is generated automatically and sent as a PDF within 30 minutes.
- 04 If generation should fail, you are not charged.
- 05 You receive the receipt by email once the report has been generated and completed.
Do you want to buy the AI Credit Risk Report (3 EUR / report)?
The report is sent to the email address you enter in Stripe's payment window. Please also check your spam folder. Questions? Write to info@creditreports.dk.
Page generated